Harry Skip Kiil Sells 1,483 Shares of Medtronic (NYSE:MDT) Stock

Key Points

• Medtronic EVP Harry Kiil sold 1,483 shares at an average price of $93.65, receiving $138,882.95. His remaining ownership fell 3.4% to 42,186 shares.
• Medtronic reported quarterly earnings of $1.45 per share on $9.76 billion in revenue, exceeding analyst expectations, while revenue grew 13.7% year over year.
• The company declared a quarterly dividend of $0.72 per share, or $2.88 annualized, representing a 3.1% yield; analysts maintain a “Moderate Buy” consensus with a $103.92 target price.

Medtronic PLC (NYSE:MDT - Get Free Report) EVP Harry Kiil sold 1,483 shares of the firm's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president directly owned 42,186 shares of the company's stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Medtronic Trading Up 0.3%

Shares of MDT traded up $0.27 during mid-day trading on Thursday, reaching $92.87. The stock had a trading volume of 10,846,470 shares, compared to its average volume of 8,857,796. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The firm has a market cap of $118.80 billion, a price-to-earnings ratio of 22.87, a P/E/G ratio of 2.14 and a beta of 0.56. The business's fifty day moving average is $88.54 and its 200 day moving average is $85.01. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54.

Medtronic (NYSE:MDT - Get Free Report) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts' consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the previous year, the firm earned $1.26 earnings per share. Medtronic's quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.97 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic's dividend payout ratio is presently 70.94%.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Raised outlook and stronger heart-device demand: Medtronic reportedly increased its financial outlook again, supported by continued demand for its cardiac products. This reinforces confidence in near-term earnings growth. Medtronic raises its outlook again as heart device demand keeps climbing
• Positive Sentiment: FDA clearance expands Hugo’s commercial opportunity: The FDA cleared Medtronic’s LigaSure RAS Maryland instrument for use with the Hugo robotic-assisted surgery system. The additional instrument expands the procedures Hugo can support and brings a vessel-sealing technology used in more than 45 million procedures to U.S. robotic surgery customers. Medtronic announces FDA clearance for LigaSure RAS Maryland instrument
• Positive Sentiment: Hugo expansion could diversify revenue: Medtronic is expanding the uses of its Hugo Surgical System, potentially increasing system adoption and recurring instrument revenue as the platform gains broader clinical utility. Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?
• Positive Sentiment: Electrophysiology momentum: A comparison with Boston Scientific indicates Medtronic is gaining share in electrophysiology and benefiting from stronger momentum across key franchises, making it a relatively attractive option within the group. BSX versus MDT: Which Electrophysiology Stock Is the Better Bet Now?
• Positive Sentiment: Experienced leadership added: Lara Barghout, former CEO of Recor Medical, was appointed president of Medtronic’s Interventional Cardiology Therapies business. Her renal-denervation and regulatory experience could support innovation and growth in cardiovascular therapies. Recor Medical ex-CEO Lara Barghout joins Medtronic
• Neutral Sentiment: Medtronic’s earnings-call commentary pointed to broad-based growth momentum, while its AI maternal-health initiative with Sonus adds another potential long-term investment theme. Medtronic earnings call signals broad-based growth momentum
• Negative Sentiment: Medtronic underperformed some medical-device peers in the prior session, indicating that investor enthusiasm remains measured despite the improving company-specific news. Medtronic stock underperforms Wednesday compared with competitors

Wall Street Analyst Weigh In

Several equities analysts have recently commented on MDT shares. BTIG Research upped their price target on Medtronic from $91.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday, September 1st. Truist Financial restated a "hold" rating and issued a $99.00 price objective (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Mizuho set a $115.00 target price on shares of Medtronic in a research report on Wednesday, September 2nd. Piper Sandler reaffirmed a "neutral" rating on shares of Medtronic in a research note on Monday, August 10th. Finally, The Goldman Sachs Group dropped their price target on shares of Medtronic from $84.00 to $83.00 and set a "neutral" rating for the company in a research report on Thursday, June 4th. Nineteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Medtronic has an average rating of "Moderate Buy" and a consensus target price of $103.92.

Institutional Investors Weigh In On Medtronic

Institutional investors and hedge funds have recently modified their holdings of the company. Bullseye Investment Management LLC purchased a new position in Medtronic during the 2nd quarter valued at about $45,000. Keystone Financial Planning Inc. acquired a new stake in shares of Medtronic during the second quarter worth about $9,889,000. Core Capital Management & Research inc. acquired a new stake in shares of Medtronic during the second quarter worth about $33,000. Tidal Investments LLC boosted its stake in shares of Medtronic by 17.5% in the second quarter. Tidal Investments LLC now owns 290,007 shares of the medical technology company's stock valued at $22,687,000 after purchasing an additional 43,207 shares during the period. Finally, National Pension Service grew its holdings in shares of Medtronic by 2.7% in the second quarter. National Pension Service now owns 3,162,805 shares of the medical technology company's stock valued at $247,426,000 after purchasing an additional 83,277 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

About Medtronic

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.